用SJP1602针对FAK/PYK2进行针对三阴性乳腺癌的抗瘤活性
Myeongjin Jeon1, Sungpyo Hong2, Hyoungmin Cho1
1Research Center, Samjin Pharm. Co., Ltd., Seoul 07794, Republic of Korea.
Current issues in molecular biology
|September 27, 2023
概括
一种新药,SJP1602,显示出治疗三阴性乳腺癌 (TNBC) 的前景. 这种聚焦粘附激酶 (FAK) 和PYK2的双重抑制剂在临床前模型中有效降低了瘤的生长和扩散.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学 是一个学科.
背景情况:
- 三阴性乳腺癌 (TNBC) 是具有有限治疗选择的侵袭性.
- 焦点粘附激酶 (FAK) 在TNBC生长和转移中发挥着关键作用.
- 现有的FAK抑制剂尚未在TNBC临床上取得成功.
研究的目的:
- 调查SJP1602的治疗潜力,一种新的FAK和PYK2双抑制剂,用于TNBC.
- 评估SJP1602在TNBC模型中的体外和体内疗效.
主要方法:
- 在体外测试评估FAK/PYK2抑制,细胞生长,迁移,入侵和3D球形形成.
- 在老鼠中进行的药理动力学研究.
- 使用TNBC异种移植模型进行体内疗效研究.
主要成果:
- 在体外,SJP1602强烈抑制了FAK和PYK2的活性.
- SJP1602证明了TNBC细胞增殖,迁移,入侵和球形形成的度依赖抑制.
- 在体内,SJP1602表现出良好的药理动力学和显著的剂量依赖性瘤生长抑制.
- 在临床前TNBC模型中,SJP1602的性能优于其他FAK抑制剂.
结论:
- SJP1602是一种强大的FAK和PYK2双抑制剂,对TNBC具有显著的临床前疗效.
- SJP1602为治疗三阴性乳腺癌提供了进一步的临床研究.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:22PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K